Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million.
Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company. It has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials and has initiated one clinical trial and another five clinical trials for its core products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers.
The Davis Polk corporate team included partners Xuelin (Steve) Wang, Yang Chu and Jason Xu, associates Jenny Ho and Michelle Chow and registered foreign lawyers Wentian Xie and Haiyang Zhao. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.
Related Posts
Yizhu Technology Completes Multi-Hundred-Million RMB Financing to Drive AI Chip Innovation (October 15, 2024)
Yizhu Technology announced completion of multi-hundred-million RMB financing led by a renowned overseas fund with participation from Shengshi Technology and Xingzhi Capital. The funding will support ongoing development and innovation of AI compute chips and system solutions, focusing on overcoming the “memory wall” and “energy wall” for
E-Tronic Provides Advanced EV Power Electronics Chips Supporting Efficient Battery Management (February 17, 2025)
Chinese startup E-Tronic specializes in power semiconductors and controller systems for the automotive industry. Their vehicle-grade 12V lithium battery management system (BMS) chip supports front-end analog acquisition, power management, intelligent watchdog, CAN/LIN communication, monitoring and diagnosis, high-side drive, and real-time clock. This enables li
Pillar Biosciences Closes $29.7 Million in Series C Financing
May 12, 2020NGS clinical cancer diagnostics company Pillar Biosciences held a Series C financing signing ceremony at its headquarters in Boston, USA, officially announcing the completion of a $29.7 million Series C financing round led by ORI Healthcare Fund, which raised Series A funding. The financing will accelerate the expansion of Pillar’s R&D pro
Connecting the Future: Web3Labs, IoTeX, and Goldford-HB Ventures Jointly Launch Global Recruitment for DePIN Project
Recently, Asia’s well-known Web3 accelerator Web3Labs officially announced that it will join forces with DePIN infrastructure leader IoTeX and venture capital firm Goldford-HB Ventures to launch a new round of global recruitment for DePIN projects. Committed to finding and cultivating project teams with innovative spirit and strong potential for joint investm